Rates of brain acetylome remodeling in a mouse model of diabetes and tauopathy

阿尔茨海默病（AD）是美国十大死因之一， 无法治愈AD的特征在于tau蛋白病，过度磷酸化的微管的积累， 相关蛋白tau（MAPT，tau），并与代谢失调有关。2型糖尿病 糖尿病（T2DM）是迟发性AD的危险因素，但两者之间的机制联系是 不清楚 翻译后蛋白质赖氨酸N（赖氨酸）乙酰化的中心代谢物乙酰辅酶A， 已被确定为中间代谢，表观遗传学， 和蛋白质稳定性。T2DM的特征是底物代谢改变， 乙酰化和脱乙酰化辅因子NAD+和乙酰辅酶A。组蛋白和tau蛋白失调 乙酰化与年龄依赖性记忆障碍有关。体外研究表明 乙酰化有助于tau蛋白的聚集位点特异性乙酰化在体内的影响 包括tau蛋白转换在内的脑蛋白是未知的。 为了研究这一点，我们开发了一种基于2H2O（稳定同位素）的质谱法， 定量蛋白质周转并评估翻译后修饰（PTM）对 体内蛋白质稳定性。本研究旨在评估乙酰化对脑蛋白质组的作用 AD的htau小鼠模型中的动力学。第一个目标是定量蛋白质组和乙酰组 饮食诱导的糖尿病和非糖尿病AD的海马和额叶皮质动力学 在小鼠中测定T2DM相关的乙酰化失调对脑蛋白质稳定性的影响。 vivo.第二个目的是评估T2DM对脑蛋白乙酰化周转的作用， vivo.研究小组还将确定T2DM相关的乙酰化改变如何有助于 tau蛋白病和认知功能下降。这些实验将确定 乙酰基组动力学方法和激励新的AD疗法的发展。

Alzheimer's disease (AD) is one of the top ten causes of death in the United States, and there is no cure. AD is characterized by tauopathy, the accumulation of hyperphosphorylated microtubule- associated protein tau (MAPT, tau), and is linked to metabolic dysregulation. Type 2 diabetes mellitus (T2DM) is a risk factor for late-onset AD, but the mechanistic link between the two is unclear. Post-translational protein lysine N(epsilon) acetylation by the central metabolite acetyl-CoA has been identified as an essential regulatory mechanism in intermediary metabolism, epigenetics, and protein stability. T2DM is characterized by altered substrate metabolism, which impacts acetylation and deacetylation co-factors NAD+ and acetyl-CoA. Dysregulated histone and tau acetylation have been linked with age-dependent memory impairment. In vitro studies suggest that acetylation contributes to tau aggregation. The in vivo impact of site-specific acetylation on brain protein, including tau turnover, is unknown. To investigate this, we developed a 2H2O (stable isotope)-based mass spectrometry method to quantify protein turnover and assess the effect of post-translational modifications (PTMs) on protein stability in vivo. The study aims to evaluate the role of acetylation on brain proteome dynamics in the htau mouse model of AD. The first aim quantifies proteome and acetylome dynamics in the hippocampus and frontal cortex of diet-induced diabetic and non-diabetic AD mice to determine the effect of T2DM-related dysregulated acetylation on brain protein stability in vivo. The second aim assesses the role of T2DM on the acetylation turnover of brain proteins in vivo. The research team will also determine how T2DM-related altered acetylation contributes to tauopathy and cognitive decline in AD. These experiments will establish the feasibility of the acetylome dynamics method and motivate the development of new AD therapies.